­ Vaccibody AS announced the appointment of Dr. Volck to its Board of Directors. Dr. Volck has over 20 years of leadership experience in the biotechnology and pharmaceutical industry. Dr. Volck has served as the President R&D at AVROBIO Inc. (Nasdaq), a clinical stage gene therapy company. Prior to this, she served as head of Research and Development, Rare Diseases, for GlaxoSmithKline. Before that, Dr. Volck was the Chief Medical Officer and Senior Vice President of Development at Swedish Orphan Biovitrum AB. She has held various positions at Amgen Inc., including Executive Development Director, Bone, Neuroscience & Inflammation and served as Nordic Medical Director and Project Director at Genzyme A/S. She currently serves as Director of Ascendis Pharma A/S (Nasdaq) and Soleno Therapeutics Inc.